(Q45072363)

9 December 2017

Expression of imatinib mesylate-targeted kinases in endometrial carcinoma (English)

1 reference

9 December 2017

1 reference

9

Karen H Lu

1 reference

9 December 2017

8

David M Gershenson

1 reference

9 December 2017

1

Brian M Slomovitz

1 reference

9 December 2017

Russell R Broaddus

2

1 reference

9 December 2017

Rosemarie Schmandt

3

1 reference

9 December 2017

Weiguo Wu

4

1 reference

9 December 2017

Jonathan C Oh

5

1 reference

9 December 2017

Lois M Ramondetta

6

1 reference

9 December 2017

Thomas W Burke

7

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

9 December 2017

1 reference

9 December 2017

95

1 reference

9 December 2017

1

1 reference

9 December 2017

32-36

1 reference

9 December 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

7 January 2021

Endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

STI571 (Gleevec) as a paradigm for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Growth factor receptors in breast cancer: potential for therapeutic intervention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Treatment of uterine papillary serous carcinoma with paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.06.052

10.1016/J.YGYNO.2004.06.052

7 January 2021

Identifiers

DOI

1 reference

9 December 2017

1 reference